MariTide
InvestigationalAlso known as: AMG 133, maridebart cafraglutide
A bispecific peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism. Unique mechanism opposite to tirzepatide. Phase 2 showed ~20% weight loss at 52 weeks with once-monthly dosing. MARITIME Phase 3 program initiated.
Research Statistics
Phase 2 bispecific GLP-1/GIPR agonist with multinational Amgen trials; novel mechanism combining two established incretin pathways with early but promising human data.
Research Dossier
Overview
What is MariTide and what does the research say?
Mechanism of Action
MariTide represents a unique approach in the incretin-based therapy space, combining GLP-1 agonism with GIP antagonism—the opposite of tirzepatide’s dual agonist mechanism.
How It Works (Simplified)
MariTide’s bispecific design targets metabolic pathways through two distinct actions:
The GLP-1 peptide portion activates GLP-1 receptors, reducing appetite, improving glucose control, and slowing gastric emptying—standard incretin effects.
The antibody portion blocks GIP receptors, potentially reducing fat storage signals and preventing GIP-driven metabolic effects—opposite to tirzepatide.
Scientific Pathways
GLP-1 Receptor Activation (Appetite & Glucose)
MariTide GLP-1 portion → GLP-1R activation → Hypothalamic satiety signaling
↓
Reduced appetite + Improved glycemic controlGIP Receptor Blockade (Fat Metabolism)
MariTide anti-GIPR antibody → GIPR blockade → Altered adipose tissue signaling
↓
Modified nutrient partitioningKey Research: Amgen Phase 2 (ADA 2025) demonstrated ~20% weight loss at 52 weeks with monthly dosing. Amgen Press Release
Important Limitations
- GIP antagonism vs agonism debate unresolved—both approaches show efficacy
- No head-to-head trials against tirzepatide or semaglutide
- Phase 3 MARITIME program ongoing; final efficacy/safety data pending (~2027)
- Long-term cardiovascular and safety outcomes not yet established
- Currently investigational—not approved for clinical use
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Titration phase beginning at 21mg monthly. GI side effects (nausea, vomiting, diarrhea) most common during initial dosing. Early appetite suppression typically observed.
Dose escalation to 35mg then 70mg. Continued weight loss trajectory. GI symptoms typically diminish as body adjusts to medication.
Maintenance dosing at 70mg monthly. Phase 2 data showed substantial and progressive weight loss through this period with no plateau.
Continued weight loss with curves still declining at 52 weeks. Mean weight loss approximately 20% in non-diabetic obesity population.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate MariTide product quality
Good Signs (4 indicators)
Warning Signs (3 indicators)
Bad Signs (4 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining MariTide with other peptides. Based on published research and mechanistic considerations.
Tirzepatide
CautionBoth target GLP-1 receptors but with opposing GIP mechanisms (MariTide antagonizes, tirzepatide agonizes). Should not be combined due to overlapping primary mechanisms.
Semaglutide
CautionBoth are GLP-1 receptor agonists. Combining would result in additive GLP-1 activation and potentially severe GI adverse events. Not recommended.
Retatrutide
CautionOverlapping GLP-1 agonism and opposing GIP mechanisms. Not suitable for combination due to pharmacological conflicts.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare MariTide
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium, NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111, Oral Amycretin, Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191, hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833, NN9838, ZP8396
A long-acting amylin analog developed by Novo Nordisk for weight management. Currently in Phase 3 trials as CagriSema (combination with semaglutide). Phase 2 data shows up to 22-25% weight loss when combined with semaglutide, potentially exceeding tirzepatide efficacy.
CagriSema
Cagrilintide-Semaglutide, NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. Phase 1b results showed 18.8% placebo-adjusted weight loss at 24 weeks, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.